This post was originally published on this site TG Therapeutics‘ umbralisib (TGR-1202), an inhibitor of the PI3K delta protein, has shown promising efficacy and safety in patients with relapsed or refractory marginal zone lymphoma, reducing cancer volume in more than half of patients in a Phase 2b trial. Findings from the ongoing trial — called UNITY-NHL (NCT02793583) — were presented at the American…
Conditions
Conditions
Study Targets Activity, Oxygen Issues in Advanced Sarcoidosis Patients
This post was originally published on this site Patients with advanced sarcoidosis have limited daily life physical activity, mostly because their lungs’ maximal oxygen uptake is reduced, a study shows. The findings of the study, “Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study,” were published in the journal Health…
2 Compounds in Coffee Seen to Slow Growth of Prostate Cancer in Early Study
This post was originally published on this site Two compounds found in coffee might be able to slow the growth and migration of prostate cancers, a pilot study conducted in drug-resistant cancer cells and a mouse model report. As such, two possible therapeutic candidates for drug-resistant prostate cancers may have been identified in this work,…
Gantenerumab Continues to Show Promise in Reduction of Amyloid Plaques
This post was originally published on this site Latest findings from the open-label extension (OLE) Phase 3 clinical trials Scarlet RoAD (NCT01224106) and Marguerite RoAD (NCT02051608) on gantenerumab (RG1450, RO4909832) continue to show significant reductions in the accumulation of amyloid plaques in patients with Alzheimer’s disease with and without amyloid-related imaging abnormalities-edema (ARIA-E). The findings…
Treading Dark Waters
This post was originally published on this site Alzheimer’s disease is cruel. And its cruelty is unparalleled, robbing patients and stripping entire families of what they hold dearest. Definite characteristics are associated with this mind-altering condition, one of which is an unfortunate outcome. But if you’re in the throes of the disease, you already know…
Faslodex-Arimidex Improves Survival in Post-menopausal Women with Advanced BC, Trial Shows
This post was originally published on this site First-line treatment with Arimidex (anastrozole) plus Faslodex (fulvestrant) prolongs the lives of post-menopausal women with hormone receptor (HR)-positive advanced breast cancer, particularly those who have never taken tamoxifen, results of a clinical trial show. The study, “Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer,” was…
Opdivo-Yervoy Combo Shrinks Aggressive Neuroendocrine Tumors, Phase 2 Trial Shows
This post was originally published on this site A combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab) reduces tumor size in four of 10 patients with aggressive neuroendocrine carcinoma, according to early results of a Phase 2 trial. The research was described in the presentation, “A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1…
Three-tiered Combination Stimulates Immune System to Attack Lymphoma Cells, Phase 1/2 Trial Shows
This post was originally published on this site A combination of oral Imbruvica (ibrutinib), intratumoral CpG, and local low-dose radiation stimulates the immune system to safely and effectively attack lymphoma cells, according to a new study. The study, “Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in…
OncoTracker Acquires Global Rights to Diagnostic Test, Possible Combo Therapy for Multiple Myeloma
This post was originally published on this site OncoTracker has acquired worldwide rights to a diagnostic test and possible triple combination therapy for patients with multiple myeloma in an agreement with the Institute for Myeloma and Bone Cancer Research. The first patent family includes the patent “Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic…
Be the Difference Foundation Brings ‘Wheel to Survive’ to Boulder, Colorado
This post was originally published on this site To celebrate ovarian cancer survivors while raising funds for research and patient programs, the Be the Difference Foundation will present its signature “Wheel to Survive” event May 19 in Boulder, Colorado. The indoor cycling fundraiser will be from 9 a.m. to noon at DEFINE Body & Mind…
Investigational Azeliragon May Lessen Cognitive Decline in Mild Alzheimer’s Disease Patients with Type 2 Diabetes, Analysis Finds
This post was originally published on this site The investigational therapy azeliragon decreased inflammation and lessened cognitive decline and dementia in patients with mild Alzheimer’s disease and type 2 diabetes, compared with a placebo, according to data from a subgroup analysis of the Phase 3 STEADFAST study. The findings were described in the presentation, “Inflammatory Biomarkers,…
Time-Restricted Feeding May Cut Tumor Risk in Obese Women, Mouse Study Suggests
This post was originally published on this site A preliminary study in mice suggests that when a person eats, and not what a person eats, may decrease the risk of breast tumors in obese women. Researchers at the University of California San Diego investigated whether time-restricted feeding (TRF) — eating all meals and snacks within…